Stempoint Capital’s Protagonist Therapeutics PTGX Stock Holding History

Stempoint Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.65M	Buy	72,577 +13,147	+22%	+$1.16M	1.46%	25
2025 Q4	$5.19M	Buy	59,430 +11,476	+24%	+$939K	0.89%	38
2025 Q3	$3.19M	Buy	47,954 +31,184	+186%	+$1.77M	0.64%	38
2025 Q2	$927K	Sell	16,770 -32,471	-66%	-$1.56M	0.3%	45
2025 Q1	$2.38M	Sell	49,241 -92,473	-65%	-$3.87M	0.76%	30
2024 Q4	$5.47M	Buy	+141,714	New	+$6.18M	1.37%	26
2024 Q1	–	Sell	-513,681	Closed	-$11.8M	–	89
2023 Q4	$11.8M	Buy	+513,681	New	+$8.99M	3.14%	7

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Stempoint Capital's PTGX Position: Q1 2026 in Review

Stempoint Capital increased its Protagonist Therapeutics (PTGX) stake by 22% in Q1 2026, buying an estimated $1.16M and bringing the position to 72,577 shares worth $7.65M. The position accounts for 1.46% of the portfolio, ranked #25.

Stempoint Capital first reported a position in PTGX in Q4 2023 and has held it in 7 quarters since. The position peaked at $11.8M in Q4 2023. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Stempoint Capital held 72,577 shares of Protagonist Therapeutics worth $7.65M as of Q1 2026.
Stempoint Capital bought 13,147 Protagonist Therapeutics shares in Q1 2026, an estimated $1.16M.
Protagonist Therapeutics made up 1.46% of Stempoint Capital's portfolio in Q1 2026, its #25 holding.
Stempoint Capital first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 7 quarters since.
Stempoint Capital's Protagonist Therapeutics position peaked at $11.8M in Q4 2023.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.